CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| S1900F | SWOG | A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study) | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1900G | SWOG | A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1900K | RTOG | A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1904 | SWOG | Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ – Making Informed Choices On Incorporating Chemoprevention Into Care (MiCHOICE) | Cancer Prevention and Control CIRB | Available to Open |
| S1905 | SWOG | A Phase I/II Study of AKR1C3-Activated Prodrug OBI‐3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL) | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1912CD | SWOG | A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) | Cancer Prevention and Control CIRB | Available to Open |
| S1914 | SWOG | A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1918 | SWOG | A Phase II/III Randomized Study of R-miniCHOP with or without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1922 | SWOG | Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI In Refractory Small Bowel Adenocarcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| S1925 | SWOG | Randomized, Phase II Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study | Adult CIRB - Late Phase Emphasis | Available to Open |